Screening for prostate cancer
173 results
1 - 100
Screening for prostate cancer
PSA for screening of prostate cancer - PSA test in prostate cancer screening
PSA screening for prostate cancer not recommended (USPSTF)- Ask-tell-ask approach to discussing prostate cancer screening
- Prostate cancer screening increases harm risk without decreasing mortality
- The full truth about prostate cancer screening is suppressed again (ERSPC)
- MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)
- Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)
- 5‐alpha‐reductase inhibitors for prostate cancer prevention
- Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
- PSA screening does not reduce mortality from prostate CA (PLCO)
- Prostate cancer
- Population screening for cancer
- PSA screening does not decrease mortality
- Low-intensity PSA-based screening does not reduce mortality, but leads to overdiagnosis and potential harm
- Impact of PSA screening on quality of life
- ACP: Discuss prostate screening with men 50-69 years old
- Prediction model can decrease prostate biopsies in men with abnormal PSA
- PSA screening has marginal effect on mortality in European study (ERSPC)
- Modelling study shows less-intense screening is okay for men with low baseline PSA levels